Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study

Abstract

Among patients with methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteremia from a prospective randomized clinical trial, acute kidney injury (AKI) rates increased with increasing vancomycin exposure, even within the therapeutic range. AKI was independently more common for the (flu)cloxacillin group. Day 2 vancomycin AUC ≥470 mg·h/L was significantly associated with AKI, independent of (flu)cloxacillin receipt.